This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Delivered as a Hybrid Event September 20-22, 2021
In-Person: September 20-21 • Virtual: September 22Aloft Boston Seaport District • Boston, MA

Mark Guerin
Chief Financial Officer at Onconova Therapeutics, Inc.

Profile

Mr. Guerin joined Onconova Therapeutics in September 2013 to augment the financial reporting, forecasting, and internal controls capabilities of the company following the IPO in July 2013, and was named Chief Financial Officer in 2016. During his tenure as CFO, Onconova has completed several financing transactions, including a rights offering, public offerings, registered direct offerings, and at-the-market offerings.  Prior to joining Onconova, Mr. Guerin worked as an interim senior finance & accounting executive facilitating the post-acquisition integration activities of newly-acquired private equity portfolio companies. Previously, Mr. Guerin was the VP Finance & CFO of Cardiokine, Inc. through that company’s filing of a New Drug Application and the sale of the company. Prior to joining Cardiokine, Mr. Guerin was Director, Financial Reporting & Internal Controls at Barrier Therapeutics, Inc. during Barrier’s IPO and follow-on offering. Mr. Guerin started his career at Coopers & Lybrand in Philadelphia. He received his bachelor’s degree in Accounting from DeSales University and has earned the CPA, CMA, CGMA, and CFM professional certifications.

Mark Guerin's Network

Agenda Sessions

  • Financing Strategies for Public Companies

    9:15am